Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > LATEST
LATEST
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 11, 2002
-
ARCHIVE BUSINESS NEWS IN BRIEF
March 11, 2002
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
March 11, 2002
-
ARCHIVE 7 Drugs Approved, Including Sivelestat
March 11, 2002
-
ARCHIVE WORLD NEWS IN BRIEF
March 11, 2002
-
ARCHIVE Committee to Propose Basic Policy for Science and Technology
March 11, 2002
-
ARCHIVE BULLETIN
March 11, 2002
-
ARCHIVE IFN Prices to Be Cut by 25%
March 11, 2002
-
ARCHIVE Maruishi: Sales, Profits Up due to Increases in Exports
March 11, 2002
-
ARCHIVE WEBSIITE NEWS
March 11, 2002
-
ARCHIVE NCC Forecasts Survival Rates for Cancer Will Double by 2015
March 11, 2002
-
ARCHIVE Gov't to Formulate Basic Policy for New Healthcare System for Elderly in FY2002
March 11, 2002
-
ARCHIVE Novartis Foundation Provides Support for 53 Researchers
March 11, 2002
-
ARCHIVE Each Drug Firm Has Tie-ups with 18 Others: FTC Survey
March 11, 2002
-
ARCHIVE DIAGNOSTIC NEWS IN BRIEF
March 11, 2002
-
ARCHIVE REGULATORY NEWS IN BRIEF
March 11, 2002
-
ARCHIVE OTS NEWS IN BRIEF
March 11, 2002
-
COMMENTARY BARKER ON DRUGS (3)
March 11, 2002
-
ARCHIVE NHI Price Revision in April Will Hit Drug Companies Hard: Mr Fujiyama of FPMAJ
March 11, 2002
-
ARCHIVE Kuraya Sanseido Aims at Consolidated Sales of \1,330 Bil. in FY2004
March 11, 2002
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…